RA, reuma, rheumatiod arthritis
Conditions
Interventions
Observational with invasive measuring.
Sponsors
AMC
Eligibility
Inclusion criteria
Inclusion criteria: Males/females suffering from RA, classified according to the 2010 ACR/EULAR classification criteria for RA, who have active disease (DAS28 „d3.2) despite adequate methorexate treatment, will be eligible for the study. Patients in ARA functional classes I, II, and III may be included. In addition, patients must fulfill the following criteria at baseline: 1. Be >18 years and < 70 years of age; 2. Use concurrent MTX treatment (5-30 mg/week; stable for at least 28 days before study initiation) during the study. Subjects may be taking NSAIDs or oral corticosteroids (prednisone equivalent < 10 mg/day), provided that the dosage has been stable for at least 28 days prior to entry; 3. Have an inflamed knee, ankle or wrist joint.
Exclusion criteria
Exclusion criteria: 1. Pregnancy; 2. Breastfeeding; 3. Subjects who are impaired, incapacitated, or incapable of completing study related assessments; 4. Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematosus); 5. Subjects who have received treatment with rituximab less than 1 year before baseline or abatacept less than 1 month before baseline; 6. Subjects who have received treatment with tocilizumab; 7. Current use of oral corticosteroids (if exceeding a prednisone equivalent of 10 mg daily) or DMARDs other than MTX; intra-articular injections of corticosteroids 28 days or less before inclusion; 8. Current use of TNF blocking agents, such as etanercept, adalimumab, infliximab, golimumab or certolizumab. Washout periods are depending on pharmacokinetic profile of the various agents; 9. Subjects with active vasculitis of a major organ system with the exception of rheumatoid nodules; 10. Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, or other medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study; 11. Subjects with a history of cancer within the last five years (other than nonmelanoma skin cell cancers cured by local resection); 12. Subjects who have clinically significant drug or alcohol abuse; 13. Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (such as chronic pyelonephritis, osteomyelitis and bronchiectasis); 14. Subjects at risk for tuberculosis (TB). Specifically, subjects with: A. A history of active TB within the last 3 years even if it was treated; B. A history of active TB > 3 years ago unless there is documentation that prior anti-TB treatment was appropriate in duration and type; C. Current clinical, radiographic or laboratory evidence of active TB; D. Latent TB, which was not successfully treated. 15. Subjects with herpes zoster or cytomegalovirus infection that resolved <2 months prior to signing informed consent; 16. Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus, hepatitis B or hepatitis C infection detected during screening; 17. Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication or who will have need of a live vaccine at any time following Day 1 of the study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The secondary objectives of this study are to: 1. Assess clinical response at week 16; 2. Identify synovial biomarkers predictive of the clinical response to tocilizumab treatment. | — |
Primary
| Measure | Time frame |
|---|---|
| The primary objective is to study changes in synovial inflammation in serial biopsy samples following the administration of tocilizumab in patients with active RA. | — |
Contacts
Public ContactP.P. Tak
Academic Medical Center (AMC), Department of Clinical Immunology and Rheumatology, P.O. Box 22660
Outcome results
None listed